{"title":"壳聚糖纳米粒子包埋低释放度丝裂霉素C分子用于膀胱内装置","authors":"D. Kavaz, Feyza Kiraç, M. Kıraç, Ashok Vaseashta","doi":"10.4236/JBNB.2017.84014","DOIUrl":null,"url":null,"abstract":"The aim of this investigation \nis preparation of Mitomycin-C encapsulated with chitosan nanoparticles synthesis using ionic gelation technique for \nintravesical controlled drug delivery \nsystems. This study was conducted in \nvitro. Cumulative amount of drug released from the nanoparticles was \ncalculated. Mitomycin-C release studies were examined for different pH values. \nDuring the drug loading and release studies, initial amount of drug was changed \n(i.e., 0.5, 1.25 and 2.5 mg) to get \ndifferent release profiles and the release studies were repeated (n = 6). The loading efficiencies of \nMitomycin-C with three different initial concentrations 0.5mg/ml, 1.25 mg/ml \nand 2.5 mg/ml into chitosan nanoparticles were 54.5%, 47.1% and 36.4%, respectively. \nFor different pH values, the cumulative releases of Mitomycin-C from chitosan \nnanoparticles were 47% and 53% for pH 6.0 and 7.4, respectively (p p san nanoparticles \nwas measured in T24 bladder cancer cell line in vitro, and the results \nrevealed that the 2.5 MMC coated Chitosan nanoparticles had better tumor \ncells decline activity. From this investigation, we conclude that the drug encapsulated synthesized chitosan nanoparticles \npossess a high ability to be used as pH and dose responsive drug \ndelivery system. This systematic investigation demonstrates a promising future \nfor the intravesical installation in treatment of the superficial bladder \ncancer.","PeriodicalId":68623,"journal":{"name":"生物材料与纳米技术(英文)","volume":"08 1","pages":"203-219"},"PeriodicalIF":0.0000,"publicationDate":"2017-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"Low Releasing Mitomycin C Molecule Encapsulated with Chitosan Nanoparticles for Intravesical Installation\",\"authors\":\"D. Kavaz, Feyza Kiraç, M. Kıraç, Ashok Vaseashta\",\"doi\":\"10.4236/JBNB.2017.84014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of this investigation \\nis preparation of Mitomycin-C encapsulated with chitosan nanoparticles synthesis using ionic gelation technique for \\nintravesical controlled drug delivery \\nsystems. This study was conducted in \\nvitro. Cumulative amount of drug released from the nanoparticles was \\ncalculated. Mitomycin-C release studies were examined for different pH values. \\nDuring the drug loading and release studies, initial amount of drug was changed \\n(i.e., 0.5, 1.25 and 2.5 mg) to get \\ndifferent release profiles and the release studies were repeated (n = 6). The loading efficiencies of \\nMitomycin-C with three different initial concentrations 0.5mg/ml, 1.25 mg/ml \\nand 2.5 mg/ml into chitosan nanoparticles were 54.5%, 47.1% and 36.4%, respectively. \\nFor different pH values, the cumulative releases of Mitomycin-C from chitosan \\nnanoparticles were 47% and 53% for pH 6.0 and 7.4, respectively (p p san nanoparticles \\nwas measured in T24 bladder cancer cell line in vitro, and the results \\nrevealed that the 2.5 MMC coated Chitosan nanoparticles had better tumor \\ncells decline activity. From this investigation, we conclude that the drug encapsulated synthesized chitosan nanoparticles \\npossess a high ability to be used as pH and dose responsive drug \\ndelivery system. This systematic investigation demonstrates a promising future \\nfor the intravesical installation in treatment of the superficial bladder \\ncancer.\",\"PeriodicalId\":68623,\"journal\":{\"name\":\"生物材料与纳米技术(英文)\",\"volume\":\"08 1\",\"pages\":\"203-219\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"生物材料与纳米技术(英文)\",\"FirstCategoryId\":\"1089\",\"ListUrlMain\":\"https://doi.org/10.4236/JBNB.2017.84014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"生物材料与纳米技术(英文)","FirstCategoryId":"1089","ListUrlMain":"https://doi.org/10.4236/JBNB.2017.84014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Low Releasing Mitomycin C Molecule Encapsulated with Chitosan Nanoparticles for Intravesical Installation
The aim of this investigation
is preparation of Mitomycin-C encapsulated with chitosan nanoparticles synthesis using ionic gelation technique for
intravesical controlled drug delivery
systems. This study was conducted in
vitro. Cumulative amount of drug released from the nanoparticles was
calculated. Mitomycin-C release studies were examined for different pH values.
During the drug loading and release studies, initial amount of drug was changed
(i.e., 0.5, 1.25 and 2.5 mg) to get
different release profiles and the release studies were repeated (n = 6). The loading efficiencies of
Mitomycin-C with three different initial concentrations 0.5mg/ml, 1.25 mg/ml
and 2.5 mg/ml into chitosan nanoparticles were 54.5%, 47.1% and 36.4%, respectively.
For different pH values, the cumulative releases of Mitomycin-C from chitosan
nanoparticles were 47% and 53% for pH 6.0 and 7.4, respectively (p p san nanoparticles
was measured in T24 bladder cancer cell line in vitro, and the results
revealed that the 2.5 MMC coated Chitosan nanoparticles had better tumor
cells decline activity. From this investigation, we conclude that the drug encapsulated synthesized chitosan nanoparticles
possess a high ability to be used as pH and dose responsive drug
delivery system. This systematic investigation demonstrates a promising future
for the intravesical installation in treatment of the superficial bladder
cancer.